Back to Search
PATRICK MCLAUGHLIN, M.D.
M.D.
Physical Medicine & Rehabilitation Physician
NPI: 1659548857IndividualAccepts Medicare
Specialties, Licenses & Credentials
Physical Medicine & Rehabilitation PhysicianPrimary
Physical Medicine & Rehabilitation
Code: 208100000X
6851422-1205(UT)48704(CO)
Education
UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, DENVER
Class of 2005
Research & Publications (20)
Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy.
PMID 19515511·Int J Radiat Oncol Biol Phys·2010
4-observational
Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor.
PMID 18813788·Int J Oncol·2008
7-preclinical
Central vs. peripheral administration of ethanol, acetaldehyde and acetate in rats: effects on lever pressing and response initiation.
PMID 18294679·Pharmacol Biochem Behav·2008
4-observational
Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
PMID 17273790·Int J Mol Med·2007
8-other
Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds.
PMID 16243441·Int J Radiat Oncol Biol Phys·2006
8-other
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
PMID 16616951·Pharmacol Biochem Behav·2006
7-preclinical
Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
PMID 16685459·Int J Oncol·2006
7-preclinical
Behavioral effects of the novel cannabinoid full agonist AM 411.
PMID 15894067·Pharmacol Biochem Behav·2005
4-observational
The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats.
PMID 16148454·Behav Pharmacol·2005
4-observational
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
PMID 15741224·Blood·2005
3-trial
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.
PMID 15629590·Int J Radiat Oncol Biol Phys·2005
4-observational
Functional anatomy of the prostate: implications for treatment planning.
PMID 16168840·Int J Radiat Oncol Biol Phys·2005
8-other
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.
PMID 15948012·Psychopharmacology (Berl)·2005
7-preclinical
The use of mutual information in registration of CT and MRI datasets post permanent implant.
PMID 15374537·Brachytherapy·2004
4-observational
Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
PMID 14654962·Int J Oncol·2004
7-preclinical
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.
PMID 14665975·Behav Pharmacol·2003
7-preclinical
Comparison of MRI pulse sequences in defining prostate volume after permanent implantation.
PMID 12377321·Int J Radiat Oncol Biol Phys·2002
4-observational
Rituximab: perspective on single agent experience, and future directions in combination trials.
PMID 11578912·Crit Rev Oncol Hematol·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 575 RIVERGATE, UNIT 204
DURANGO, CO 81301 - Phone
- (801) 573-4021
Quick Facts
- NPI
- 1659548857
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 21
- Publications
- 20
Are you this provider?
Claim Your Profile